Gilead Sciences (NASDAQ:GILD) Price Target Raised to $170.00 at Rothschild & Co Redburn

Gilead Sciences (NASDAQ:GILD) had its target price boosted by Rothschild & Co Redburn from $159.00 to $170.00 in a report released on Tuesday,MarketScreener reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Rothschild & Co Redburn’s target price suggests a potential upside of 10.75% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. BMO Capital Markets raised their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. HSBC increased their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Oppenheimer lifted their price objective on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Finally, Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Twenty-three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $152.96.

Gilead Sciences Trading Down 1.1%

NASDAQ GILD traded down $1.78 during trading on Tuesday, reaching $153.49. 298,257 shares of the stock traded hands, compared to its average volume of 7,693,300. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The firm has a market cap of $190.44 billion, a price-to-earnings ratio of 22.69, a price-to-earnings-growth ratio of 2.06 and a beta of 0.36. The stock’s 50-day moving average price is $131.66 and its 200 day moving average price is $122.97. Gilead Sciences has a fifty-two week low of $93.37 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts predict that Gilead Sciences will post 7.95 EPS for the current year.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 288,891 shares of company stock worth $40,303,946. 0.27% of the stock is owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently modified their holdings of the company. Quattro Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter worth approximately $26,000. Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $28,000. GoalVest Advisory LLC boosted its holdings in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the third quarter valued at approximately $26,000. Finally, Financial Consulate Inc. grew its stake in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.